Join our daily newsletter At The Bell to receive exclusive market insights
- TALi Digital (TD1) receives the Therapeutic Goods Administration’s (TGA) tick of approval for its software product ReadyAttentionGo!
- ReadAttentionGo! is designed to be a cognitive trainer to develop the attention span of children between three and ten years old through digitised and gamified tasks
- The tablet software has now received certification and approval as a class one medical device, to be used under the direction of a healthcare professional
- With the TGA approval under its belt, TALi Digital has the green light to promote ReadyAttentionGo! to the Australian market
- TD1 shares are up 50 per cent to 0.3 cents at 3:28 pm AEDT
Health tech company TALi Digital (TD1) has received approval from the Therapeutic Goods Administration (TGA) for its software product ReadyAttentionGo!
ReadAttentionGo! has been designed as a cognitive trainer to develop the attention span of children between three and ten years old through digitised and gamified tasks.
The tablet program is to be used under the direction of a healthcare professional, rather than as a stand-alone diagnostic or screener. The program has been created to involve “play-based” interactions, complementary to existing therapy.
The company has now received certification and approval for the tablet product as a class one medical device.
The TALi team completed the design and development of the product in February as a ‘software as a medical device’ product, which has been deemed compliant under the quality management system to ensure a safe and effective product design.
With the TGA approval under its belt, TALi Digital can promote ReadyAttentionGo! to the Australian market.
TD1 shares were up 50 per cent to 0.3 cents at 3:28 pm AEDT.
